Array BioPharma reports rise in Q2 revenue
Array BioPharma reported revenue of $23.2m for the second quarter of fiscal 2012, up from revenue of $16.5 million for the same period in fiscal 2011.
The net loss was significantly reduced to $3.8m for the second quarter, compared to a net loss of $12.4m for the second quarter in fiscal 2011.
The net loss improved due to increased revenue recognized from up-front and milestone payments during the current quarter.
The company reported revenue of $45.4m for the six-month period ended 31 December 2011, compared to revenue of $35.0m for the same period in fiscal 2011.
Net loss for the six months ended 31 December 2011 was $7.4m compared to a net loss of $23.1m for the corresponding period in fiscal 2011.
Related Insight
Suppliers Directory
BaseCon - IT Pharma Solutions
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT solutions by using state-of-the-art technology combined with detailed knowledge of the requirements in the pharmaceutical sector.
Drug Research > Drug Discovery & Development > Suppliers
EggCentris - Reproductive Function Testing
EggCentris is a contract research laboratory for the analysis of the reproductive function, male and female fertility, and embryo toxicity, with unique in vitro technology for fast, early-stage determination of toxicity.
Drug Research > Drug Discovery & Development > Suppliers
BSL BIOSERVICE- Safety and Activity Testing Services
BSL BIOSERVICE Scientific Laboratories is an internationally recognised Contract Research Organization (CRO) and a member of an international laboratory network.
Drug Research > Drug Discovery & Development > Suppliers
Trinean - UV-VIS Spectral Analysis of DNA/RNA, Protein or Small Compounds
Trinean develops and produces a new approach for high throughput full scan UV-VIS spectral analysis of microliter droplets of DNA/RNA, protein or small compounds.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
SynBiosys™ Drug Delivery Systems
Published by InnoCore Technologies BV
Drug Research > Drug Discovery & Development > White Papers
ILS Client List
Published by Investigator Location Services
Drug Research > Drug Discovery & Development > White Papers
Protecting Sensitive Information in Life Sciences Organisations
Published by Brainloop
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.